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Maropitant, aber nicht Ondansetron hemmt die durch Tranexamsäure verursachte Emesis. Eine 
kontrollierte verblindete randomisierte Crossover-Studie 
 
Ziel dieser Studie war es, die Häufigkeit von Tranexamsäure (TXA) -induzierter Übelkeit und 
Erbrechen nach prophylaktischer Anwendung von zwei Antiemetika, Ondansetron und 
Maropitant, im Vergleich zu einer Kontrollkochsalzlösung zu bewerten. In dieser prospektiven, 
randomisierten Vergleichsstudie wurden acht erwachsene, zu Versuchszwecken gezüchtete 
Beagles einer Behandlung ausgesetzt. Hunde erhielten dreimal jeweils drei Behandlungen nach 
einer Auswaschphase. Entweder Maropitant 1 mg/kg, Ondansetron 0,2 mg/kg oder Salzlösung 
wurde intravenös (IV) gegeben und zehn Minuten später TXA 50 mg/kg IV. Der Schweregrad 
der Übelkeit wurde mit einer visuellen Analogskala (VAS) bewertet. Die statistische 
Signifikanz wurde auf p<0,05 festgelegt.  
Insgesamt haben 5 von 8 Hunden (62,5%) erbrochen, jedoch keiner nach Maropitant. Es gab 
eine signifikante Reduktion in der Häufigkeit von Erbrechen nach Maropitant (p<0,0001), 
nicht jedoch nach Ondansetron oder Kochsalzlösung (p=0,53). Die höchsten Übelkeits-VAS 
erschienen in den ersten 5 Minuten. Die Wirkung von Maropitant und Ondansetron gegen 
Kochsalzlösung auf den Schweregrad der Übelkeit war statistisch nicht signifikant (p=0,069). 
Somit verhinderte Maropitant wirksam das Erbrechen im Vergleich zu Ondansetron und 
Placebo. 
 
Erbrechen, Übelkeit, Antifibrinolytika, Nebenwirkungen, Hunde 
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Maropitant but not ondansetron inhibits tranexamic acid-evoked emesis. A controlled blinded 
randomized crossover trial 
 
The aim of this study was to evaluate the incidence of tranexamic acid (TXA)-induced nausea 
and vomiting after the prophylactic use of two antiemetics, ondansetron, and maropitant, 
compared to saline. This was prospective, blinded, placebo-controlled, randomized, crossover 
study. Eight adult, purpose-bred, Beagle dogs were exposed to treatment. Dogs received three 
treatments on three occasions with a 3-week washout period. Either maropitant (1 mg/kg), 
ondansetron (0.2 mg/kg) or saline solution was given intravenously (IV), followed 10 minutes 
later by 50 mg/kg IV TXA. The severity of nausea was assessed by the blind observer for 30 
minutes with a visual analog scale (VAS). Statistical significance was set at p<0.05.  
None of the dogs vomited after maropitant. Emesis occurred in 5 out of 8 dogs (62.5%). There 
was a significant effect on vomiting of maropitant against saline (p<0.0001) but not for 
ondansetron against saline (p=0.53). The highest nausea VAS were recorded during the first 5 
minutes after TXA.  The effect of maropitant and ondansetron against saline on the severity of 
nausea was not statistically significant (p=0.069). 
In conclusion, the neurokinin 1 receptor antagonist maropitant, administered IV ten minutes 
before 50 mg/kg TXA was effective in preventing vomiting compared to ondansetron and 
placebo.  
 
vomiting, nausea, antifibrinolytic agents, side effects, canine 
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Abstract  
Objective- To evaluate the incidence of tranexamic acid (TXA)-induced nausea and vomiting after 
the prophylactic use of two antiemetics, ondansetron, and maropitant, compared to saline. 
Design- Prospective, blinded, placebo-controlled, randomized, crossover study. 
Setting- University research facility. 
Animals- Eight adult, purpose-bred, Beagle dogs.  
Intervention- Dogs received three treatments on three occasions with a 3-week washout period. 
Either maropitant (1 mg/kg), ondansetron (0.2 mg/kg) or saline solution was given intravenously 
(IV) in equal volumes, followed 10 minutes later by 50 mg/kg IV TXA. A blinded observer 
evaluated the dogs for signs of vomiting and nausea for 30 minutes. The severity of nausea was 
assessed with a visual analog scale (VAS) and recorded at baseline prior TXA, and at the end of 
three observational periods: 0-5, 5-15, 15-30 minutes after TXA. A generalized linear mixed effect 
model was used to assess for group and period effects. Statistical significance was set at p < 0.05. 
 
Measurements and Main Results- None of the dogs vomited after maropitant. Emesis occurred 
in 5 out of 8 dogs (62.5%), a median (range) of one time (1 – 2) after ondansetron and one time 
(1-3) after saline. There was a significant effect on vomiting of maropitant against saline 
(p<0.0001) but not for ondansetron against saline (p=0.53). The highest nausea VAS were 
recorded during the first 5 minutes after TXA with a significant reduction of VAS variability in 
the maropitant group (p=0.003).  The effect of maropitant and ondansetron against saline on the 
severity of nausea was not statistically significant (p=0.069).  
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Conclusion- The neurokinin 1 receptor antagonist maropitant at the dose used, administered IV 
ten minutes before 50 mg/kg TXA was effective in preventing vomiting compared to ondansetron 
and placebo. Our results support the prophylactic IV administration of maropitant in dogs that are 
scheduled to receive TXA.  
 
Keywords: vomiting, nausea, antifibrinolytic agents, side effects, canine 
 
Abbreviations 
 
IV intravenous 
TXA tranexamic acid 
VAS visual analog scale  
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Introduction  
 Tranexamic acid (TXA) is an antifibrinolytic drug, which reversibly adheres to the lysine-
binding site on plasminogen and inhibits its activation into plasmin. In consequence, TXA results 
in suppression of fibrinolysis and stabilization of the clot.1 A large body of scientific evidence from 
human medicine has been published showing that TXA reduces blood loss and decreases blood 
transfusions requirements.2-5 Veterinarians have gained interest in antifibrinolytic drugs and 
multiple studies supporting their use in dogs have been published. To date, TXA has been shown 
effective as an antifibrinolytic drug in dogs infected with Angiostrongylus vasorum as well as in 
Greyhounds undergoing ovariohysterectomy and limb amputations. 6-8 Moreover, antifibrinolytic 
drugs such as TXA, have the potential to reduce blood loss in dogs with spontaneous 
hemoperitoneum, as hyperfibrinolysis has been found to be an important cause of hemorrhage in 
these circumstances.9 
 In people and dogs, intravenous (IV) administration of TXA is well known to induce nausea 
and vomiting.10,11 Nausea is a very unpleasant experience affecting the comfort of the patient. 
Analysis of a questionnaire for pet owners about perioperative nausea has shown agreement for 
additional financial contribution to decrease the occurrence of nausea in their pets.a Although 
vomiting in healthy patients may be harmless, in critically ill patients it can lead to a marked 
increase in morbidity and mortality due to major complications, such as aspiration pneumonia, 
esophagitis, and esophageal stricture.12-14 Additionally, in patients with head trauma, vomiting 
raises the intracranial pressure, which can lead to further deterioration of the neurologic status.15  
 Various and potent antiemetics are available in dogs, working at different parts of the 
emetogenic pathway. Maropitant, a neurokinin 1 receptor antagonist, has been effective against 
multiple centrally and peripherally acting emetics as well as against clinical causes of vomiting.16  
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Ondansetron as a 5-hydroxytryptamine (serotonin) 3 receptor antagonist is used as the first line 
treatment of drug-induced emesis, especially in chemotherapy patients and in the prophylaxis of 
postoperative nausea and vomiting.17 Aprepitant, a neurokinin 1 receptor antagonist, used in 
human medicine, was able to decrease kaolin intake in rats previously exposed to TXA, while 
ondansetron and domperidone (a dopamine 2 receptor antagonist) failed to do so.18 Rats are a 
non-emetic species and pica behaviors are assessed as indicators of nausea in preclinical studies. 
However, some doubt arose whether results of preclinical studies assessing potential emetogenic 
substances in rats with pica behaviors can directly be translated to the emetic effect of these 
substances in other species.19  
 The goal of the present study was to evaluate the effectiveness of prophylactic maropitant 
and ondansetron in preventing TXA-induced vomiting in a blinded placebo-controlled crossover 
study in Beagle dogs. The secondary aim was the evaluation of the effects of both treatments on 
nausea after TXA. The study hypothesis was that maropitant would be able to suppress TXA 
evoked emesis while ondansetron and placebo would not affect it. 
 Material and methods  
 This project has been approved by the xx Ethics Committee on Animal Research of the xx 
(authorization number xx).  
Animals  
 Eight healthy, purpose-bred, Beagle dogs (4 intact females, 4 intact males), aged 6.5 (6-
6.5) years old (median (range)), and weighing 13.1 kg (10.7-16.6 kg) were included in the study. 
Dogs were considered healthy based on physical examination and basic blood work (packed cell  
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volume, total plasma protein, and venous blood gas analysis).b Dogs were permanently housed in 
an approved facility, four same-sex individuals per cage, with free access to outside fenced area, 
unlimited access to water and commercial dietc provided once a day at 12:00. Since the 
experimental procedures were performed in the morning, all dogs received 100 g of soft dog foodd 
approximately 20 minutes before the start of the study. The research was conducted at the dogs' 
usual residence by the experimental facility, in a dedicated room well known to the animals. Dogs 
were moved one at the time to the experimental room and returned to their conventional cages 
once the study was concluded. A week before the study inauguration, dogs were familiarized with 
the study investigators and habituated to the experimental design. This time also allowed the 
investigators to familiarize with the animals individual behavior.  
Randomization  
 This study was performed as a randomized, prospective, crossover, blinded, placebo-
controlled trial. Block randomization with balanced permutations was performed using an online-
based software.e 
Treatments  
 Animals were allocated to receive one of three possible treatments on the single occasion, 
with a three-week washout period between treatments. Either 1 mg/kg of maropitantf 0.2 mg/kg 
ondansetrong or 3 ml saline (0.9% sodium chloride)h was administered IV on each occasion 
through an aseptically placed 22-Ga x 2.5 cm cephalic vein catheter.i All medications were 
equalized to a total volume of 3 ml with 0.9 % sodium chloride (if needed) and administered over 
2 minutes. Ten minutes later all animals received 50 mg/kg TXAj IV over 2 minutes.  
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Study outcomes  
 One blinded study investigator (MK) was responsible for all assessments of the dogs for 
30 minutes. The primary study outcome was the occurrence of vomiting. Additionally, the number 
of episodes and the time of their occurrence were documented. Vomiting was defined as the 
expulsion of gastrointestinal content through the mouth, accompanied by forceful, and sustained 
abdominal muscle contractions. The secondary study outcome was the severity of nausea assessed 
by means of a Visual Analog Scale (VAS)20 at four-time points: baseline prior to administration 
of TXA, and during the defined time periods 0-5, 5-15 and 15-30 minutes after TXA. The VAS 
score was made by placing a mark on a 100mm line at the end of each observational period. More 
intense nausea received higher marks (0-100 mm). Signs interpreted as nausea included: lip and 
nose licking, increased frequency of swallowing, ptyalism, gulping, panting, restlessness, whining 
and winking.  
Sample size calculations 
 The assumptions were 100% incidence of vomiting (without antiemetic) according to 
former study in Beagle dogs using the same dose regime of TXA.11 Results of a priori power 
analysis indicated that eight dogs would be sufficient to detect a reduction of vomiting from 100% 
in untreated to 10% in treated dogs with a power of 80% and a type one error of 5 %.  
Statistical analysis  
 To assess the group effect (maropitant/ondansetron/saline) and the period effect (A/B/C) 
on vomiting (YES or NO) and on VAS (mm), a generalized linear mixed effect model (binomial) 
was used. The period effect was assessed by the Wald Test. All analyses were performed with the 
software package R version 3.3.3k and the package geepack.21 Graphs were created with graphpad.l 
Statistical significance was set at p < 0.05.  
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Results 
Vomiting episodes 
 None of the eight dogs receiving maropitant vomited, while after ondansetron and saline 
treatments five out of eight dogs vomited (3 males, 2 females) (62.5% occurrence). There was a 
significant effect of maropitant against saline (p<0.0001) but not for ondansetron against saline 
(p=0.53). There was no evidence of a period effect (p=0.14). The frequency of vomiting is 
presented in Figure 1. The first emetic episode after the end of TXA administration occurred within 
55 (33-90) seconds (median (range)) for ondansetron and within 76 (31- 192) seconds after saline. 
Severity of nausea 
 The highest nausea VAS were recorded during the first five minutes after TXA (Figure 2). 
One female dog that never vomited displayed a VAS of 6 mm after saline pretreatment in the first 
five minutes after TXA administration and no nausea at all during the other two exposures. The 
effect of maropitant and ondansetron against saline was not statistically significant (p = 0.069). 
However, in the maropitant group a significant reduction of VAS variability could be detected 
(p=0.003). A significant period effect could be observed (p<0.0001).  
Discussion  
 Maropitant administered IV ten minutes in advance abolished TXA-induced vomiting in 
dogs. Ondansetron did not reduce the incidence of vomiting compared to saline. The dogs that 
received maropitant still displayed signs of nausea with a lower variability in VAS scores than 
with the other treatments. Overall, the severity of nausea as assessed by VAS was considered mild  
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to moderate across all the treatments. Emetic episodes were short, fast in onset and occurred up to 
three times, all within the first four minutes after the end of TXA administration. 
 The neurokinin 1 receptor-mediated pathway has been hypothesized as the potential 
mechanism behind TXA-evoked emesis in rats, in which pica behaviors were assessed.18 Kaolin 
intake, a marker of pica behaviors, is a model for nausea in rats. In the mentioned study, kaolin 
intake was decreased by concomitant administration of TXA and aprepitant, whereas no difference 
was found for ondansetron and domperidone. Additionally, immunohistochemical staining of the 
brain after TXA alone and after TXA with aprepitant, has found that TXA with aprepitant 
decreased the neuronal activity in both the area postrema (chemoreceptor trigger zone) and the 
nucleus tractus solitarius (vomiting center).18 Our results in dogs corroborate the findings of 
Kakiuchi in rats,18 and likely a neurokinin 1 receptor pathway is involved in nausea and vomiting 
side effects of TXA. Involvement of a serotonin pathway seems less likely but cannot be excluded, 
despite the fact that the potent serotonin receptor antagonist ondansetron did not affect nausea and 
vomiting in our study. It is important to mention that we chose a one standard dose of ondansetron 
(0.2 mg/kg) due to the clinical nature of our research.22 In a low dose cisplatin model of nausea 
and vomiting in dogs, ondansetron, at the dose of 0.5 mg/kg IV, was as effective as maropitant in 
suppressing emesis and highly more effective in suppressing nausea (90% vs. 25% AUC 
reduction).17 It is possible that higher doses of ondansetron may have produced greater anti-emetic 
and anti-nausea effects. Perhaps more time would have been necessary for ondansetron to 
distribute to receptor sites within the brain or peripheral sites of action to counteract the rapid 
action of TXA. On the contrary, in the study of Santos et al. in cats, waiting for 30 minutes after 
0.22 mg/kg intramuscular ondansetron injection did not diminish vomiting after  
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dexmedetomidine.23 If ondansetron would require more time to be effective against the TXA in 
our study, this would render the drug less practical in a clinical situation. TXA is most frequently 
used in emergency situations and a time delay for ondansetron to prevent emesis could be 
detrimental.  
 In a study assessing the vomiting effects of TXA,11a single TXA bolus of 50 mg/kg has 
been shown to induce vomiting in all ten Beagle dogs. In the same study, reduced dose rates caused 
a lower incidence of vomiting, and it was hypothesized that a dose dependency exists, though 
vomiting with dosages as low as 15 mg/kg has also been reported.24 Most recently, the dose of 50 
mg/kg TXA was further investigated in 137 dogs, in which the incidence of vomiting was 84.7%. 
25 In our study, the administration of 50 mg/kg TXA over 2 minutes resulted in an incidence of 
vomiting of only 62.5%. These findings suggest that either we injected the TXA slower than in the 
previous studies leading to lower peak plasma concentrations of TXA, or individual differences in 
sensitivity to the vomiting side effects of TXA exist. The differentiation between these two 
reasons, however, cannot be answered by the current study.  
 In veterinary medicine, further work is needed to establish required plasma levels as well 
as intravenous dosing regimes of TXA.  In an in vitro study TXA plasma levels required to inhibit 
tissue plasminogen-induced hyperfibrinolysis in dogs were assessed. 26 The calculated IV dose of 
TXA to reach the required plasma levels for dogs were as high as 150 mg/kg. In another study, 
where TXA was used to inhibit hyperfibrinolysis in Angiostrongylus vasorum infected patients, 
some dogs required cumulative doses of up to 80 mg/kg TXA IV, to stop bleeding.8 Whether 
maropitant is also effective in preventing TXA induced vomiting at dosages beyond 50 mg/kg 
remains to be determined and was beyond the scope of the present study. In dogs, recent  
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pharmacokinetic data showed that a bolus of 20mg/kg TXA IV reaches plasma concentrations that 
are higher than the ones necessary to inhibit fibrinolysis. m 
 Interestingly, the dogs receiving maropitant still displayed signs of nausea. It is a well-
known phenomenon in humans undergoing chemotherapy that the occurrence of nausea may 
persist despite the inhibition of emesis with antiemetic drugs.27 After all, nausea seems to be a 
more complicated phenomenon involving still undetermined neurotransmitters and mechanisms, 
which until date, are not fully understood.27 Another explanation for persistent nausea could be the 
short interval between the administration of maropitant and TXA. When in one study maropitant 
was administered subcutaneously, incomplete absorption and thus incomplete effect at the time of 
assessment has been hypothesized.28 Nevertheless, in our study maropitant has been administered 
IV and therefore effective plasma levels should have been reached imminently according to 
pharmacokinetic data.17 It is likely that the time interval of ten minutes between maropitant and 
TXA administration could be further shortened. Yet, this study was not designed to answer that 
question. 
 In humans, female patients are reported to be more prone to develop postoperative nausea 
and vomiting. The reason for this is unknown.29 In our study, of the three dogs that did not vomit, 
one was male and two were females. One of the two females that did not vomit displayed only 
minimal (6 mm on VAS scale) signs of nausea after TXA. In veterinary medicine, there are no 
data available about the prevalence of nausea and patient-specific risk factors (sex, breed, size, 
type of surgery, medications).  
Our study has some limitations. Overall, we report a lower incidence of vomiting than 
announced elsewhere.11 The effects of maropitant on induction of vomiting could therefore only  
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be tested in five out of eight dogs. However, maropitant was effective in suppressing emesis and 
reducing the variability in severity of nausea when compared to ondansetron and saline treatment. 
Although crossover designs allow to decrease the number of required animals because inter-
individual differences are eliminated, the period effect found in this study is a common problem. 
The small sample size of eight dogs led to an imbalanced group allocation per period (Figure 2) 
and made it impossible to disentangle the effect of period and group on VAS. Additional individual 
effects like familiarization of the dogs to the experimental model or systematic intra-observer 
differences in VAS allocation between the three observation periods can occur. Screening for 
nausea remains difficult, and only subjective measures are possible in veterinary medicine. In this 
study, a Visual Analog Scale was used as a severity scale for nausea. Though VAS is the most 
commonly used tool across research about emesis, its subjective nature can lead to misdiagnosis, 
over- or underestimations.27 In the current study consistently the same, blinded observer assessed 
all dogs after all treatments to exclude inter-observer variability. No validated method for nausea 
assessment is available in veterinary medicine at the moment. A recent study identified blood 
biomarkers such as cortisol and arginine vasopressin as an objective method for nausea screening 
in a low-dose cisplatin model.30 The biomarkers had a weak but significant correlation with VAS 
score in the clinical trial performed by the same group later on.17  
 The current study supports the use of maropitant to inhibit TXA-induced vomiting in dogs. 
A gastrointestinal disturbance is the main side effect in human patients using TXA in their 
everyday life for menometrorrhagia or other coagulopathies.10 The result of the current study 
supports further research using the neurokinin 1 receptor antagonist aprepitant for the treatment of 
TXA-induced nausea and vomiting in people. 
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In conclusion, the neurokinin 1 receptor antagonist maropitant administered IV at the dose 
used, ten minutes before 50 mg/kg TXA successfully inhibited vomiting compared to ondansetron 
and placebo. Our results support the prophylactic IV administration of maropitant in dogs that are 
scheduled to receive TXA.   
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Footnotes 
a Kraus B & Cazlan C. Assessment of dog owner concern regarding perioperative nausea and vomiting and willingness 
to pay for anti-emetic treatment [abstract]. Presented at the American College of Veterinary Anesthesia and Analgesia 
Annual Meeting, Washington DC, USA; 2015. 
b RAPIDPoint 500 Blood Gas System, Siemens, xx 
c commercial food formula xx, Sensitive, xx, xx 
d Hill`s a/d, Prescription Diet Canine/Feline; 156 g (5.5 oz), xx 
e www.randomization.com, last entry 18.12.2016, 23:23:26 
f Cerenia, Maropitant, Zoetis, xx 
g xx, Ondansetron, xx 
h Sodium chloride 0.9%, xx 
i Terumo, Surflo, intravenous catheter, xx 
j xx, Tranexamic Acid, 100mg/ml, xx 
k R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. URL https://www.R-project.org/ 
l  Graphpad Prism, Graphpad Software Inc., xx 
m Osekavage KE, Brainard BM, Almoslem MJ et al. Pharmacokinetics of single dose IV tranexamic acid in healthy 
adult dogs [abstract]. Presented at the International Veterinary Emergency and Critical Care Symposium, Nashville, 
TN, USA; 2017 
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Figure Legends 
 
Figure 1: The frequency of vomiting per study group and with individual signs for each dog. 
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Figure 2: Visual Analog Scale in mm (VAS) for nausea at four-time points: at baseline before 
TXA (VAS 0), during 0 - 5 minutes (VAS 5), 5-15 minutes (VAS 15) and 15-30 minutes (VAS 
30) post-TXA administration per study group. Each graph represents one period (A/B/C) with 
individual signs for each dog. 
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